Stay updated on Pembrolizumab and Chemotherapy in Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Chemotherapy in Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Chemotherapy in Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study plan for the clinical trial investigating the efficacy of pembrolizumab and doxorubicin hydrochloride or anti-estrogen therapy in treating patients with triple-negative or hormone receptor-positive metastatic breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:51.000Z thumbnail image
  4. Check
    5 days ago
    No Change Detected
  5. Check
    6 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participants in the clinical study.
    Difference
    48%
    Check dated 2024-05-22T21:28:49.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:37:03.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Chemotherapy in Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Chemotherapy in Breast Cancer Clinical Trial page.